# Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

> **NCT07480863** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 65 (estimated)

## Conditions studied

- Marginal Zone Lymphoma(MZL)

## Interventions

- **DRUG:** Orelabrutinib
- **DRUG:** Zuberitamab
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Prednisoneacetatetablets

## Key facts

- **NCT ID:** NCT07480863
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2029-10-01
- **Final completion:** 2029-10-02
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07480863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07480863, "Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07480863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*